Jun 2026 (Q2 FY26) — Aug 6, 2026
INmune Bio Inc. Q2 FY26 — Regulatory Progress for Ebstracell and Positive EXPRO Phase 2 Data
Read the full callINmune Bio (INMB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
INmune Bio earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -1.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.65 +3.12% · +$0.05
Performance −11.8% 1Y
1Y: $1.87 on 14 Oct 2025 → $1.65. High $2.51 (8 Sept 2026), low $1.12 (27 Mar 2026).
- Previous close
- $1.6
- 52-week range
- $1.12 – $2.51
- One year
- −14.51%
Overview
- Symbol
- INMB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
INmune Bio earnings calls (INMB)
Financials
What the filings say
Net profit, year on year: +95% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | — | 0 | 0 | — | — | 0 | — | — |
| Operating profit | -12 | -9 | -10 | -25 | -7 | -5 | -6 | -1 |
| Operating margin | — | — | −19810.0% | — | — | — | — | — |
| Other income | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 0 | — | 0 | — | — | — | — | — |
| Net profit | -12 | -9 | -10 | -24 | -6 | -5 | -5 | -1 |
| EPS ($ per share) | -0.60 | — | -0.43 | -1.05 | -0.24 | — | -0.20 | -0.05 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -14 | -21 | -33 | -64 | -91 | -121 | -163 | -209 |
| Total liabilities | 1 | 1 | 2 | 20 | 22 | 19 | 7 | 9 |
| Fixed assets | — | — | — | — | — | — | — | 1 |
| Total assets | 17 | 24 | 41 | 100 | 82 | 57 | 40 | 32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2 | -5 | -9 | -29 | -23 | -12 | -33 | -23 |
| Cash from investing | — | — | — | -15 | — | — | — | -1 |
| Cash from financing | 1 | 12 | 24 | 96 | 1 | -4 | 18 | 28 |
| Net cash flow | — | — | — | 53 | -23 | -16 | -15 | 4 |
| Capital expenditure | — | — | — | — | — | — | — | -1 |
| Free cash flow | — | — | — | — | — | — | — | -24 |
Insider filings
3 filings, all on Jul 2, 2026.
Open market
decisions to buy or sellNobody bought or sold INMB on the open market in this window. The filings below are 3 option exercises.
Compensation
not trading decisions- 3
- Option exercise — converted options into shares
Latest filings (6)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 2, 2026 | Moss David J Chief Executive Officer | Option exercise | 9,014 | $12.6K |
| Jul 2, 2026 | Lowdell Mark William Chief Scientific Officer | Option exercise | 7,211 | $10.1K |
| Jul 2, 2026 | Juda Scott Director | Option exercise | 14,801 | $20.7K |
| Sep 30, 2024 | Moss David J Chief Financial Officer | Purchase | 10,000 | $52.9K |
| Sep 12, 2024 | Moss David J Chief Financial Officer | Purchase | 7,690 | $49.0K |
| Sep 12, 2024 | Tesi Raymond Joseph President and CEO | Purchase | 15,380 | $98.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Inmune Bio, Inc.
Free account. Everything above stays public.
Write why you follow Inmune Bio, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading